Impact of Hemodilution on Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia

被引：0
|
作者：
Tettero, Jesse [1 ,2 ]
Heidinga, Maaike [1 ]
Mocking, Tim [1 ]
Kelder, Angele [1 ]
Scholten, Willemijn [1 ]
Snel, Alexander [1 ]
Ngai, Lok Lam [1 ]
Bachas, Costa [1 ]
van de Loosdrecht, Arjan [1 ]
Ossenkoppele, Gert [1 ]
de Leeuw, David [1 ]
Janssen, Jeroen [3 ]
Cloos, Jacqueline [1 ]
机构：
[1] Amsterdam UMC, Amsterdam, Netherlands
[2] Virginia Tech, FBRI Canc Res Ctr, Washington, DC USA
[3] Radboudumc, Nijmegen, Netherlands
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
AML; acute myeloid leukemia; hemodilution; measurable residual disease; MRD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-348
引用
收藏
页码：S307 / S308
页数：2
相关论文
共 50 条
  • [31] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
    Aitken, Marisa J. L.
    Ravandi, Farhad
    Patel, Keyur P.
    Short, Nicholas J.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [32] Measurable residual disease testing for personalized treatment of acute myeloid leukemia
    Ehinger, Mats
    Pettersson, Louise
    APMIS, 2019, 127 (05) : 337 - 351
  • [33] Widespread use of measurable residual disease in acute myeloid leukemia practice
    Epstein-Peterson, Zachary D.
    Devlin, Sean M.
    Stein, Eytan M.
    Estey, Elihu
    Tallman, Martin S.
    LEUKEMIA RESEARCH, 2018, 67 : 92 - 98
  • [34] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
    Marisa J. L. Aitken
    Farhad Ravandi
    Keyur P. Patel
    Nicholas J. Short
    Journal of Hematology & Oncology, 14
  • [35] Measurable residual disease in pediatric acute myeloid leukemia: a systematic review
    Segerink, W. H.
    de Haas, V
    Kaspers, G. J. L.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (04) : 451 - 459
  • [36] Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia
    Bellos, Frauke
    Alpermann, Tamara
    Gouberman, Elena
    Haferlach, Claudia
    Schnittger, Susanne
    Haferlach, Torsten
    Kern, Wolfgang
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2012, 82B (05) : 295 - 304
  • [37] Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia
    Gui, Gege
    Hourigan, Christopher S.
    CANCER JOURNAL, 2022, 28 (01) : 73 - 77
  • [38] Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions
    Moritz, Jennifer
    Schwab, Antonia
    Reinisch, Andreas
    Zebisch, Armin
    Sill, Heinz
    Woelfler, Albert
    BIOMEDICINES, 2024, 12 (03)
  • [39] Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia
    Ding, Yangyang
    Liu, Zelin
    Wang, Huiping
    Xiong, Shudao
    Zhai, Zhimin
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (05) : 340 - 347
  • [40] Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia
    Zhou, Y.
    Othus, M.
    Araki, D.
    Wood, B. L.
    Radich, J. P.
    Halpern, A. B.
    Mielcarek, M.
    Estey, E. H.
    Appelbaum, F. R.
    Walter, R. B.
    LEUKEMIA, 2016, 30 (07) : 1456 - 1464
12345